These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28316212)

  • 1. [Evaluation and classification of drug therapy for breast cancer with bone-only metastasis].
    Meng XY; Song ST
    Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):161-165. PubMed ID: 28316212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and treatment of osteoblastic metastasis in patients with breast cancer].
    Meng XY; Song ST
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):401-405. PubMed ID: 29936763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CT findings of bone metastasis].
    Nosaki T; Murai T; Okumura A; Furuki T; Mori K; Tsuji S; Nakanishi K; Kobayashi M; Fukui A; Fujii K
    Rinsho Hoshasen; 1989 Sep; 34(9):991-7. PubMed ID: 2810844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
    Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
    Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
    Wood R; Mitra D; de Courcy J; Iyer S
    Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A long survival of a patient with poor performance status who suffered from advanced right breast cancer with multiple lung metastases controlled by trastuzumab as a key drug].
    Fujikawa T; Mukai K; Tanaka A; Abe T; Yoshimoto Y; Tada S; Maekawa H; Shimoike N; Tanaka H; Kawashima T; Yokota T
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):1009-12. PubMed ID: 22705704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
    Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
    Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
    Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
    Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
    Suvannasankha A; Chirgwin JM
    Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
    Niraula S; Ocana A
    Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients.
    Oruç Z; Kaplan MA; Arslan Ç
    Expert Opin Pharmacother; 2018 Aug; 19(12):1305-1316. PubMed ID: 30129373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.